Galectin Therapeutics Inc. (GALT) Ownership
GALT ownership summary
as of October 17, 2026- Institutions
- 15.6% of shares outstanding
- Insiders
- 52.80% of shares outstanding
- Shares outstanding
- 100.8M
- Float
- 47.9M shares available to trade
- Short interest
- 11.96% 9.2M shares short
- Days to cover
- 29.01 short interest down 1.4% vs prior month
- Institutions 15.64%
- Insiders 52.80%
- Other investors 31.56%
GALT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 2.96% | 3.0M | $10.8M | +2.2M (+273.9%) | June 30, 2026 |
| 2 | Vanguard Capital Management, LLC | 2.15% | 2.2M | $7.8M | +201,523 (+10.2%) | June 30, 2026 |
| 3 | Geode Capital Management, LLC | 1.30% | 1.3M | $4.7M | +695,608 (+113.5%) | June 30, 2026 |
| 4 | Advisor Group Holdings, Inc. | 1.19% | 1.2M | $4.4M | +81,055 (+7.2%) | June 30, 2026 |
| 5 | Marshall Wace Asset Management Ltd | 0.82% | 831K | $3.0M | −388,902 (−31.9%) | June 30, 2026 |
| 6 | Sontag Advisory LLC | 0.72% | 722K | $2.6M | — | June 30, 2026 |
| 7 | State Street Corp | 0.56% | 568K | $2.1M | +309,347 (+119.7%) | June 30, 2026 |
| 8 | Commonwealth Equity Services, LLC | 0.40% | 407K | $1.5M | +40,000 (+10.9%) | June 30, 2026 |
| 9 | Northern Trust Corp | 0.38% | 387K | $1.4M | +256,097 (+196.3%) | June 30, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 0.36% | 366K | $1.3M | +62,235 (+20.5%) | June 30, 2026 |
| 11 | Vanguard Portfolio Management, LLC | 0.33% | 328K | $1.2M | +327,766 (0.0%) | June 30, 2026 |
| 12 | Two Sigma Investments LLC | 0.32% | 318K | $1.2M | −148,818 (−31.9%) | June 30, 2026 |
| 13 | LPL Financial Corp | 0.28% | 285K | $1.0M | +18,180 (+6.8%) | June 30, 2026 |
| 14 | CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 0.26% | 261K | $945,892 | +132,648 (+103.1%) | June 30, 2026 |
| 15 | Vivaldi Capital Management, LLC | 0.26% | 259K | $936,074 | +54,514 (+26.7%) | March 31, 2026 |
| 16 | Sovran Advisors, LLC | 0.26% | 258K | $933,949 | +167 (+0.1%) | June 30, 2026 |
| 17 | Geneos Wealth Management Inc | 0.24% | 240K | $870,346 | −500 (−0.2%) | June 30, 2026 |
| 18 | UBS Group AG | 0.22% | 219K | $793,935 | +39,578 (+22.0%) | June 30, 2026 |
| 19 | RETIREMENT GUYS FORMULA LLC | 0.21% | 211K | $764,012 | +23,991 (+12.8%) | June 30, 2026 |
| 20 | Citadel Advisors Llc | 0.20% | 199K | $719,298 | −91,659 (−31.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 4.4M shares and 4 cut 630K.
GALT top mutual fund and ETF holders
17 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 1.51% | 1.5M | $5.5M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.18% | 1.2M | $4.3M | −13,696 (−1.1%) | September 30, 2026 |
| 3 | Fidelity Small Cap Index | 0.52% | 520K | $1.9M | +2,219 (+0.4%) | July 31, 2026 |
| 4 | iShares Russell 2000 Growth ETF | 0.31% | 313K | $1.1M | −396 (−0.1%) | September 30, 2026 |
| 5 | Vanguard Russell 2000 ETF | 0.27% | 275K | $997,238 | +5,500 (+2.0%) | August 31, 2026 |
| 6 | Fidelity Extended Market Index | 0.26% | 264K | $955,850 | −1,419 (−0.5%) | August 31, 2026 |
| 7 | iShares Russell 2000 Value ETF | 0.16% | 157K | $567,696 | +238 (+0.2%) | September 30, 2026 |
| 8 | iShares Micro-Cap ETF | 0.15% | 151K | $547,829 | −1,044 (−0.7%) | September 30, 2026 |
| 9 | Schwab Small Cap Index | 0.12% | 116K | $421,357 | — | August 31, 2026 |
| 10 | Fidelity Total Market Index | 0.10% | 97K | $349,884 | +1,239 (+1.3%) | August 31, 2026 |
| 11 | iShares Russell 2000 Small-Cap Idx Instl | 0.09% | 90K | $324,269 | — | August 31, 2026 |
| 12 | Fidelity Series Total Market Index | 0.08% | 82K | $297,560 | +3,897 (+5.0%) | August 31, 2026 |
| 13 | Nuveen Small Cap Blend Idx R6 | 0.06% | 64K | $230,630 | — | August 31, 2026 |
| 14 | Goldman Sachs Absolute Ret Trckr Instl | 0.05% | 48K | $173,872 | +28,208 (+142.3%) | June 30, 2026 |
| 15 | EQ/2000 Managed Volatility IB | 0.05% | 48K | $172,623 | — | August 31, 2026 |
| 16 | Xtrackers Russell 2000 ETF 1C | 0.04% | 44K | $158,679 | +1,895 (+4.5%) | August 31, 2026 |
| 17 | Horizon Kinetics Medical ETF | 0.04% | 42K | $153,676 | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
GALT insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-06 | Kary Eldred | Buy | $2.70 | 300 | $810 |
| 2026-01-06 | Jack W Callicutt | Sell | $3.67 | 20,354 | $74,699 |
| 2026-01-06 | Joel Lewis | Sell | $3.58 | 37,698 | $134,959 |
| 2026-01-06 | Khurram Jamil | Sell | $3.65 | 21,446 | $78,278 |
| 2026-01-05 | Jack W Callicutt | Sell | $3.90 | 25,732 | $100,355 |
| 2026-01-05 | Joel Lewis | Sell | $3.91 | 27,731 | $108,428 |
| 2026-01-05 | Khurram Jamil | Sell | $3.90 | 25,499 | $99,446 |
| 2026-01-02 | Jack W Callicutt | Sell | $4.20 | 13,914 | $58,439 |
| 2026-01-02 | Joel Lewis | Sell | $4.20 | 18,571 | $77,998 |
| 2026-01-02 | Khurram Jamil | Sell | $4.20 | 13,055 | $54,831 |
| 2025-12-23 | Kary Eldred | Buy | $3.73 | 700 | $2,611 |
| 2025-12-17 | Harold H Shlevin | Sell | $7.04 | 24,499 | $172,473 |
| 2025-12-17 | Joel Lewis | Sell | $7.06 | 7,829 | $55,273 |
| 2025-12-17 | Khurram Jamil | Sell | $7.04 | 19,442 | $136,872 |
| 2025-12-16 | Fund L.P. 10X | Sell | $6.66 | 30,681 | $204,335 |
| 2025-12-09 | Harold H Shlevin | Sell | $6.27 | 16,790 | $105,273 |
| 2025-12-08 | Harold H Shlevin | Sell | $5.98 | 159,000 | $950,820 |
| 2025-12-03 | Fund L.P. 10X | Sell | $5.73 | 120,000 | $687,600 |
| 2025-12-02 | Fund L.P. 10X | Sell | $5.47 | 30,000 | $164,100 |
| 2025-11-13 | Khurram Jamil | Sell | $5.47 | 121,117 | $662,510 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
GALT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns GALT
Institutional investors own 15.6% of Galectin Therapeutics's shares and insiders 52.80%. The largest holder is BlackRock Inc with 2.96% of the shares (3.0M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 4 reduced their stake in the latest filings. Short interest is 11.96% of the float, or 29.01 days of average trading volume. The share count rose 189.8% since 2014.
Related: GALT analyst forecast, GALT key metrics. See the GALT stock overview for the latest quote and news.
GALT ownership FAQ
Who owns the most Galectin Therapeutics stock?
The largest shareholders of Galectin Therapeutics are BlackRock Inc (2.96%), Vanguard Capital Management, LLC (2.15%), Geode Capital Management, LLC (1.30%), Advisor Group Holdings, Inc. (1.19%), Marshall Wace Asset Management Ltd (0.82%).
What percentage of Galectin Therapeutics is owned by institutions?
Institutions hold 15.6% of Galectin Therapeutics's shares outstanding; insiders hold 52.80%.
Which funds own Galectin Therapeutics?
The largest fund holders of Galectin Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (1.51%), iShares Russell 2000 ETF (1.18%), Fidelity Small Cap Index (0.52%), iShares Russell 2000 Growth ETF (0.31%), Vanguard Russell 2000 ETF (0.27%).
What is Galectin Therapeutics's short interest?
9.2M shares of Galectin Therapeutics were sold short, 11.96% of the float; at the average daily volume it would take 29.01 days to cover.
Are insiders buying or selling Galectin Therapeutics?
Of the latest 20 reported insider transactions in Galectin Therapeutics (since November 13, 2025), 2 were purchases and 18 were sales.
How many shares of Galectin Therapeutics are outstanding?
Galectin Therapeutics has 100.8M shares outstanding, of which 47.9M are in the public float.